FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office has granted European Patent No. 3568465, titled "Methods of Enhancing Fibroblast Therapeutic Activity." The patent covers methods of augmenting the efficacy of fibroblasts for the regeneration of cells and/or tissues by contacting the fibroblasts with platelet rich plasma and one or more cytokines, including fibroblast growth factor alpha (FGF-alpha) or fibroblast growth factor beta (FGF-beta), with additional claims directed to angiogenesis and the regeneration of spinal discs.